Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will release its full year 2021 results on March 31, 2022. A conference call will follow at 8:30 a.m. EDT, accessible via phone and webcast. Interested parties can dial +1 (409) 220-9054 for U.S. access or +44 (0) 8000 323836 for international calls, using conference ID 6590614. The company specializes in immuno-oncology, leveraging its ROCK® platform to develop innovative therapies that harness the innate immune system to target various tumors. Further information is available on their website.

Positive

• Affimed is positioned as a leader in immuno-oncology with its clinical-stage ICE® molecules.
• The ROCK® platform shows promise in generating customized therapies targeting hematologic and solid tumors.

Negative

• None.

HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2021 results and corporate update on Thursday, March 31, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference conference ID 6590614 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of the company’s website at https://www.affimed.com/investors/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed release its full year 2021 results?

Affimed will release its full year 2021 results on March 31, 2022.

What is the conference call date and time for Affimed's financial results?

The conference call will take place on March 31, 2022, at 8:30 a.m. Eastern Daylight Time.

How can I access Affimed's conference call?

You can access the conference call via phone at +1 (409) 220-9054 for U.S. callers or +44 (0) 8000 323836 for international callers, referencing conference ID 6590614.

What platform does Affimed use for its innovative cancer therapies?

Affimed uses its proprietary ROCK® platform to develop therapies that harness the innate immune system.